MIGUEL
QUIJADA ÁLAMO
Investigador en el periodo 2017-2023
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (2)
2017
-
Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia
British Journal of Cancer, Vol. 117, Núm. 2, pp. 256-265
-
Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia
Journal of Hematology and Oncology, Vol. 10, Núm. 1